Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
University of Utah Families of Spinal Muscular Atrophy Sigma Tau Pharmaceuticals, Inc. Abbott |
---|---|
Information provided by: | University of Utah |
ClinicalTrials.gov Identifier: | NCT00227266 |
This is a multi-center trial to assess safety and efficacy of a combined regimen of oral valproic acid (VPA) and carnitine in patients with Spinal Muscular Atrophy (SMA) 2 to 17 years of age. Cohort 1 is a double-blind placebo-controlled randomized intention to treat protocol for SMA "sitters" 2 - 8 years of age. Cohort 2 is an open label protocol for SMA "standers and walkers" 3 - 17 years of age to explore responsiveness of efficacy outcomes. Outcome measures will include blood chemistries, functional testing, pulmonary function testing, electrophysiological evaluations, PedsQL quality of life assessment, quantitative assessments of survival motor neuron (SMN) mRNA from blood samples, growth and vital sign parameters. Six centers will enroll a total of 90 patients.
Condition | Intervention | Phase |
---|---|---|
Spinal Muscular Atrophy |
Drug: Valproic Acid and Levocarnitine |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Crossover Assignment, Efficacy Study |
Official Title: | Multi-Center Phase II Trial of Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy (SMA CARNI-VAL Trial) |
Enrollment: | 90 |
Study Start Date: | September 2005 |
Study Completion Date: | November 2007 |
Primary Completion Date: | November 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Cohort 1a: Placebo Comparator
For six months, Cohort 1 pts are randomized into placebo or treatment. After 6 months, all pts are on treatment. Cohort 2 pts are on open-label treatment throughout
|
Drug: Valproic Acid and Levocarnitine
VPA,sprinkle cap; Levocarnitine, syrup; dosage is by weight
|
Cohort 1b: Active Comparator
For six months, Cohort 1 pts are randomized into placebo or treatment. After 6 months, all pts are on treatment. Cohort 2 pts are on open-label treatment throughout.
|
Drug: Valproic Acid and Levocarnitine
VPA,sprinkle cap; Levocarnitine, syrup; dosage is by weight
|
Cohort 2: Experimental
For six months, Cohort 1 pts are randomized into placebo or treatment. After 6 months, all pts are on treatment. Cohort 2 pts are on open-label treatment throughout.
|
Drug: Valproic Acid and Levocarnitine
VPA,sprinkle cap; Levocarnitine, syrup; dosage is by weight
|
This is a multi-center phase II trial of a combined regimen of oral valproic acid (VPA) and carnitine in patients with Spinal Muscular Atrophy (SMA) 2 to 17 years of age. Cohort 1 is a double-blind placebo-controlled randomized intention to treat protocol for SMA "sitters" 2 - 8 years of age. Subjects will undergo two baseline assessments over 4 to 6 week period, then will be randomized to treatment or placebo for the next six months. All subjects will then be placed on active treatment for the subsequent six month period. Cohort 2 is an open label protocol for SMA "standers and walkers" 3 - 17 years of age to explore responsiveness of efficacy outcomes. Subjects will undergo two baseline assessments over a four to six week period, followed by one year active treatment with VPA and carnitine. Outcome measures are performed every 3 to 6 months, and include blood chemistries, functional testing, pulmonary function testing, electrophysiological evaluations, PedsQL quality of life assessment, quantitative assessments of survival motor neuron (SMN) mRNA from blood samples, growth and vital sign parameters. Six centers will enroll a total of 90 patients.
Ages Eligible for Study: | 2 Years to 17 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Cohort 1
Cohort 2
Exclusion Criteria:
Cohort 1
Cohort 2
United States, Maryland | |
Johns Hopkins University | |
Baltimore, Maryland, United States, 21287 | |
United States, Michigan | |
Children's Hospital of Michigan | |
Detroit, Michigan, United States, 48201 | |
United States, Ohio | |
Ohio State University | |
Columbus, Ohio, United States, 43210-1228 | |
United States, Utah | |
University of Utah/Primary Children's Medical Center | |
Salt Lake City, Utah, United States, 84132 | |
United States, Wisconsin | |
University of Wisconsin Children's Hospital | |
Madison, Wisconsin, United States, 53792-9988 | |
Canada, Quebec | |
Hospital Sainte-Justine | |
Montreal, Quebec, Canada, H3T 1C5 |
Principal Investigator: | Kathryn J Swoboda, M.D. | University of Utah/Primary Children's Medical Center |
Responsible Party: | University of Utah ( Kathryn J. Swoboda, M.D., Associate Professor, Pediatric Neurology ) |
Study ID Numbers: | 13698 |
Study First Received: | September 23, 2005 |
Last Updated: | December 23, 2007 |
ClinicalTrials.gov Identifier: | NCT00227266 |
Health Authority: | United States: Food and Drug Administration |
Spinal Muscular Atrophy (SMA) SMA Type 2 SMA Type 3 |
Pathological Conditions, Anatomical Spinal Cord Diseases Spinal muscular atrophy Central Nervous System Diseases Degenerative motor system disease Neurodegenerative Diseases Valproic Acid Motor neuron disease Progressive spinal muscular atrophy |
Signs and Symptoms Neuromuscular Diseases Muscular Atrophy, Spinal Neurologic Manifestations Atrophy Motor Neuron Disease Carnitine Muscular Atrophy |
Neuromuscular Manifestations Neurotransmitter Agents Vitamin B Complex Tranquilizing Agents Molecular Mechanisms of Pharmacological Action Growth Substances Nervous System Diseases Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Depressants |
Enzyme Inhibitors Antimanic Agents Pharmacologic Actions Vitamins Therapeutic Uses GABA Agents Micronutrients Central Nervous System Agents Anticonvulsants |